Scarica l'app Stockscreener
11.87
2.41%
-0.18
Oric Pharmaceuticals Inc Borsa (ORIC) Ultime notizie
Oric Pharmaceuticals, Inc. (ORIC) Stock Analysis: 74% Potential Upside Sparks Investor Interest - DirectorsTalk Interviews
Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Oric Pharmaceuticals director Heyman sells shares worth $80,430 - Investing.com
ORIC Pharmaceuticals: Transition To Late-Stage Development Presents Upside - Seeking Alpha
Short Interest in Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) Grows By 19.6% - MarketBeat
ORIC Pharmaceuticals (ORIC) Is Up 32.5% After J&J Lung Cancer Collaboration and Pipeline UpdateWhat's Changed - Sahm
ORIC Pharmaceuticals Stock Pre-Market (-6.1%) : Form 144 Filings Signal Intent to Sell - Trefis
First Week of March 20th Options Trading For Oric Pharmaceuticals (ORIC) - Nasdaq
Volume Summary: Is ORIC Pharmaceuticals Inc forming higher highs and higher lows2025 Analyst Calls & Fast Gaining Stock Strategy Reports - baoquankhu1.vn
Is Roma Green Finance Limited gaining market shareJuly 2025 Trends & Free Community Consensus Stock Picks - baoquankhu1.vn
Assessing ORIC Pharmaceuticals (ORIC) Valuation After Fresh Buy Ratings And Johnson & Johnson Collaboration - Sahm
Why ORIC Pharmaceuticals (ORIC) Is Up 36.3% After New Cancer Data And Analyst Buzz - Yahoo Finance
H.C. Wainwright reiterates Buy rating on ORIC Pharmaceuticals stock By Investing.com - Investing.com Canada
ORIC Pharmaceuticals provides 2025 operational highlights, upcoming milestones - MSN
Oric Pharmaceuticals (NASDAQ:ORIC) Sees Large Volume IncreaseStill a Buy? - MarketBeat
Precision Killers: Why Big Pharma is Betting Billions to Beat a $170B Patent Cliff - marketscreener.com
ORIC: Advancing two late-stage oncology drugs with pivotal data and trials expected by 2027 - TradingView — Track All Markets
Wedbush Reaffirms Outperform Rating for Oric Pharmaceuticals (NASDAQ:ORIC) - MarketBeat
Wedbush Reiterates Outperform Rating for ORIC at $20 | ORIC Stoc - GuruFocus
ORIC Pharmaceuticals reports progress on cancer drug candidates By Investing.com - Investing.com Nigeria
(ORIC) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
ORIC Pharmaceuticals reports progress on cancer drug candidates - Investing.com
ORIC® Pharmaceuticals Provides Operational Highlights for 2025 and Anticipated Upcoming Milestones - Sahm
Oric Pharmaceuticals (NASDAQ:ORIC) Earns Overweight Rating from Analysts at Piper Sandler - Defense World
Oric Pharmaceuticals (NASDAQ:ORIC) Trading 7.8% HigherShould You Buy? - MarketBeat
Oric Pharmaceuticals, Inc. (ORIC) Stock Analysis: A Biotech Gem with 148% Upside Potential - DirectorsTalk Interviews
Oric Pharmaceuticals (NASDAQ:ORIC) Upgraded by Piper Sandler to Strong-Buy Rating - MarketBeat
Why ORIC Pharmaceuticals Inc. stock attracts global investors2025 Price Targets & High Win Rate Trade Alerts - Улправда
Is ORIC Pharmaceuticals Inc. stock a buy before product launchesQuarterly Trade Report & Capital Efficient Trading Techniques - Улправда
Will ORIC Pharmaceuticals Inc. (4TZ) stock gain from green policiesEarnings Miss & Stock Timing and Entry Methods - Улправда
Options Flow: Will ORIC Pharmaceuticals Inc. (4TZ) stock gain from green policies2025 EndofYear Setup & Daily Technical Stock Forecast Reports - ulpravda.ru
Oric Pharmaceuticals (NASDAQ:ORIC) Shares Gap UpWhat's Next? - MarketBeat
How ORIC Pharmaceuticals Inc. stock reacts to Fed rate cutsVolatility Trading Techniques & Superior Capital Trading Plans - ulpravda.ru
Piper Sandler Initiates Coverage on ORIC with Overweight Rating and $22 PT | ORIC Stock News - GuruFocus
Piper Sandler initiates ORIC Pharmaceuticals stock with Overweight rating By Investing.com - Investing.com Canada
Piper Sandler initiates ORIC Pharmaceuticals stock with Overweight rating - Investing.com India
ORIC® Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
ORIC Pharmaceuticals shares surge on potential data leak - MSN
Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World
Oric Pharmaceuticals’ 2025 Restructuring: Potential Risks and Financial Implications - MSN
How to Invest in the U.S. Biotech Sector in 2026? Jefferies: Focus on These 6 Top Picks, 7 High-Potential Stocks, and 5 Key Acquisition Targets - 富途资讯
Squarepoint Ops LLC Invests $1.08 Million in Oric Pharmaceuticals, Inc. $ORIC - Defense World
(ORIC) and the Role of Price-Sensitive Allocations - Stock Traders Daily
ORIC Pharmaceuticals (ORIC) surges as intriguing ESMO Asia data for Enozertinib prompts Wells Fargo to assign higher value - MSN
Will ORIC Pharmaceuticals Inc. stock benefit from green energy trendsWatch List & AI Optimized Trading Strategy Guides - Улправда
Is ORIC Pharmaceuticals Inc. stock a buy on dipsDollar Strength & Growth-Oriented Investment Plans - DonanımHaber
Why retail investors favor ORIC Pharmaceuticals Inc. stockMarket Activity Report & Weekly Stock Breakout Alerts - DonanımHaber
How ORIC Pharmaceuticals Inc. stock reacts to job market dataExit Point & High Yield Stock Recommendations - DonanımHaber
Will ORIC Pharmaceuticals Inc. stock benefit from infrastructure spendingDividend Hike & Free Technical Confirmation Trade Alerts - DonanımHaber
Oric Pharmaceuticals (ORIC) Stock Analysis: Exploring a 157% Upside Potential in the Biotech Arena - DirectorsTalk Interviews
How strong is ORIC Pharmaceuticals Inc. stock revenue growth2025 Momentum Check & AI Powered Market Entry Ideas - Улправда
ORIC Pharmaceuticals Earnings Notes - Trefis
4.64%
1.71%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):